What Is Semaglutide?

Semaglutide is one of the most talked-about prescription medicines of the decade. People ask whether it is the same as Ozempic, whether it is “just a diabetes drug,” how much weight it actually produces, and whether the new pill is as strong as the shot. This guide answers those questions with trial data and FDA labeling—not social-media lore.

If you want the broader class overview first, start with what is a GLP-1 medication?. For the dual-agonist alternative people often compare it with, see what is tirzepatide?.

Educational only. This is not medical advice. Do not start, stop or change any medication without guidance from a licensed clinician who knows your history.

What is semaglutide, in one paragraph?

Semaglutide is a long-acting medicine that acts like GLP-1 (glucagon-like peptide-1), a hormone your small intestine releases after you eat. As a GLP-1 receptor agonist, it attaches to the same receptors the natural hormone uses. That helps the pancreas release insulin when blood sugar is high, reduces glucagon, slows how quickly food leaves the stomach, and signals brain pathways that regulate appetite. Most weight loss comes from eating less, not from “burning fat” in a special way. The STEP 1 authors put it plainly: weight loss “stems from a reduction in energy intake owing to decreased appetite.”

How does semaglutide work in the body?

Cleveland Clinic’s overview of GLP-1 agonists describes four overlapping jobs that apply to semaglutide:

1. More insulin when glucose is high. That softens post-meal blood-sugar spikes and is why hypoglycemia risk is relatively low when the drug is used alone.
2. Less glucagon. Less sugar released from the liver after meals.
3. Slower gastric emptying. Food stays in the stomach longer, which prolongs fullness—and also helps explain nausea and bloating early on.
4. Stronger satiety signals. Many people describe quieter “food noise,” though that phrase is patient language, not a formal trial endpoint.

Natural GLP-1 breaks down in minutes. Semaglutide is engineered to last much longer, which is why weekly injection products can work with one dose a week, and why oral forms need special absorption technology.

Obesity clinicians such as Dr. Spencer Nadolsky, in educational videos like The Metabolic Impact of GLP-1s on Obesity, repeatedly stress the same practical point: these drugs mainly reduce calorie intake, so protein intake and resistance training still matter if you want to protect muscle while weight comes down.

Brand names: Ozempic, Wegovy, Rybelsus and the pill

The same molecule can wear different brand names for different FDA-approved uses. That is the single biggest source of confusion online.

Product	Active ingredient	Typical form	Main FDA-approved use (US)
Ozempic	Semaglutide	Weekly injection	Type 2 diabetes (and related heart/kidney risk reduction in labeled patients)
Rybelsus	Semaglutide	Daily tablet	Type 2 diabetes
Wegovy	Semaglutide	Weekly injection (including higher-strength Wegovy HD)	Chronic weight management; heart-risk reduction; MASH (injection, accelerated approval)
Wegovy pill	Semaglutide	Daily tablet	Chronic weight management; heart-risk reduction

Prescribing Ozempic only for weight loss is off-label. The NIH encourages patients to ask openly when a medicine is being used that way. For a full 2026 roster of what is and is not labeled for weight management, see which GLP-1s are FDA-approved for weight loss.

Who is semaglutide for?

NIDDK says clinicians may prescribe a weight-management medication for adults with a BMI of 30 or more, or 27 or more with a weight-related condition such as high blood pressure or type 2 diabetes. Wegovy injection is also approved for certain adolescents aged 12 and older. Medications are meant to sit alongside a reduced-calorie diet and more physical activity—not replace them.

NIDDK is blunt about intent: never take a weight-management drug only to change appearance.

Who should not use it

FDA labels for Wegovy contraindicate use in people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2), based on rodent thyroid C-cell tumor findings. NIH guidance also says weight-loss medicines should not be used in pregnancy or when planning pregnancy, and are not recommended while breastfeeding. A history of pancreatitis, gallbladder disease, severe GI disease, kidney problems or diabetic retinopathy needs a careful clinician conversation.

What do the major trials show?

STEP 1: weight loss without diabetes

Published in the New England Journal of Medicine in 2021, STEP 1 enrolled 1,961 adults without diabetes who had a BMI of 30 or more (or 27 or more with a weight-related condition). Everyone also received lifestyle counseling (about a 500-calorie daily deficit and encouragement toward 150 minutes of weekly activity). Semaglutide started low and rose gradually to a 2.4 mg weekly maintenance dose.

After 68 weeks:

• Average weight change: −14.9% with semaglutide vs −2.4% with placebo (estimated treatment difference −12.4 percentage points).
• Lost ≥5%: 86.4% vs 31.5%.
• Lost ≥10%: 69.1% vs 12.0%.
• Lost ≥15%: 50.5% vs 4.9%.
• Lost ≥20%: 32.0% vs 1.7% (supportive endpoint).
• Absolute change: about −15.3 kg vs −2.6 kg.

Waist circumference, blood pressure, lipids, CRP and physical-function scores also favored semaglutide. Among people with prediabetes at baseline, 84.1% on semaglutide had normal blood sugar by week 68, versus 47.8% on placebo.

SELECT: heart outcomes without diabetes

SELECT tested whether the weight-management dose also protects the heart. It enrolled 17,604 adults aged 45 or older with preexisting cardiovascular disease, BMI ≥27, and no diabetes. Over a mean follow-up of 39.8 months, a primary major adverse cardiovascular event (CV death, nonfatal MI, or nonfatal stroke) occurred in 6.5% on semaglutide 2.4 mg versus 8.0% on placebo—a 20% relative risk reduction (hazard ratio 0.80; 95% CI 0.72–0.90; P<0.001). That result underpins Wegovy’s heart-risk reduction indication.

Cardiovascular death alone did not meet the hierarchical superiority threshold (HR 0.85; P=0.07), so later confirmatory secondary endpoints were not formally declared superior under the trial’s testing rules—even though some were directionally favorable.

Newer labeled uses: MASH, oral Wegovy, Wegovy HD

As of late 2025 and 2026, the DailyMed Wegovy label lists additional indications beyond classic weight management:

• MASH (formerly NASH): Wegovy injection received accelerated approval for adults with noncirrhotic metabolic dysfunction–associated steatohepatitis and moderate-to-advanced fibrosis (F2–F3). Continued approval may depend on confirmatory benefit.
• Wegovy pill: Approved December 22, 2025—the first oral GLP-1 receptor agonist labeled for weight management. Novo Nordisk’s SEC filing cited a 16.6% mean weight loss in the OASIS 4 program for the oral product. Absorption rules are strict (empty stomach, limited water, waiting before food or other oral medicines).
• Wegovy HD 7.2 mg: FDA approved a higher weekly injection dose for adult weight reduction and maintenance under its National Priority Voucher program, offering another option for some adults after clinician review.

Approvals change; always check the current label with your clinician.

How is treatment usually started?

Labels use a gradual dose-escalation schedule so the body can adapt and gastrointestinal side effects are less intense. Clinicians sometimes stay longer on a step if nausea is disruptive. This article does not prescribe doses or schedules—that belongs to the person writing your prescription and the official label they follow.

People on X and other platforms often ask “what dose should I be on?” The honest answer is: whatever your clinician and the labeled product instruct for your indication and tolerance—not a screenshot from a stranger.

Common side effects and serious risks

Common (especially early and after increases)

In STEP 1, gastrointestinal events led the list:

Event	Semaglutide	Placebo
Nausea	44.2%	17.4%
Diarrhea	31.5%	15.9%
Vomiting	24.8%	6.6%
Constipation	23.4%	9.5%

Most events were mild to moderate and temporary. Still, 4.5% stopped semaglutide because of GI side effects versus 0.8% on placebo. Overall treatment discontinuation from adverse events was 7.0% vs 3.1%.

Practical strategies—smaller low-fat meals, hydration, slower titration when needed—are covered in GLP-1 nausea: why it happens and how to manage it and our managing side effects guide.

Less common but important

• Gallbladder problems: Gallbladder-related disorders occurred in 2.6% on semaglutide vs 1.2% on placebo in STEP 1 (mostly gallstones), consistent with rapid weight loss risk.
• Pancreatitis: Mild acute pancreatitis was confirmed in three semaglutide participants in STEP 1; seek urgent care for severe persistent abdominal pain.
• Kidney injury: Often tied to dehydration from vomiting or diarrhea.
• Diabetic retinopathy: Cleveland Clinic notes possible worsening in some people with diabetes—another reason for follow-up eye care when relevant.
• Thyroid C-cell tumor warning: Boxed warning based on rodent data; human relevance is unknown, hence the MTC/MEN 2 restriction.

In SELECT, adverse events leading to permanent discontinuation were more common with semaglutide (16.6%) than placebo (8.2%), reflecting longer exposure and GI intolerance in a large cardiovascular population.

Semaglutide vs tirzepatide (brief)

People comparing the two usually care about three differences:

1. Mechanism: Semaglutide is GLP-1-only; tirzepatide is a dual GIP/GLP-1 agonist.
2. Trial averages: SURMOUNT-1 reported mean losses of 15.0% / 19.5% / 20.9% at 5 / 10 / 15 mg over 72 weeks versus 3.1% placebo—higher top-dose averages than STEP 1, but not a head-to-head trial in people without diabetes.
3. Extra labeled uses: Wegovy carries heart-risk reduction and MASH indications; Zepbound (tirzepatide) is also approved for moderate-to-severe obstructive sleep apnea in adults with obesity.

For a structured comparison, use our semaglutide vs tirzepatide guide and the companion article what is tirzepatide?.

Cost, shortages and compounded products

Cash and insured prices move quickly. Manufacturer direct-to-patient programs and savings cards have lowered some self-pay costs in 2025–2026; details change. See semaglutide cost without insurance and the GLP-1 cost guide.

Supply has improved for many brand products compared with the worst shortage years, but local availability still varies. The FDA continues to warn that compounded semaglutide products are not FDA-approved, have not been reviewed for safety, effectiveness or quality before marketing, and have been linked to dosing errors. “Research only” vials sold online are a separate red flag. Stick to a licensed clinician and a state-licensed pharmacy for FDA-approved products whenever possible.

What the first weeks usually feel like

Online conversations (including posts on X that ask “what is semaglutide used for?” or whether hair shedding is “from the drug”) cluster around a few practical themes: appetite drop, nausea after greasy meals, constipation, and fear of rare eye or thyroid headlines. Summarizing those questions is more useful than quoting individuals.

Patterns that match the trial and advisory literature:

• Appetite often falls before the scale moves a lot. Reduced intake is the mechanism; early weeks can feel like “I forget to eat” as much as “I am dieting.”
• Nausea and fullness are dose-change problems more than steady-state problems for many people. Holding an escalation until symptoms settle is a clinician decision, not a DIY schedule.
• Hair shedding, when it happens, is often discussed as a telogen-effluvium-type response to rapid weight loss and lower protein intake rather than a unique toxin effect of semaglutide. That does not mean ignore it—flag it with your clinician and review nutrition.
• Eye headlines (including rare NAION discussions in the wider GLP-1 literature) scare people into stopping effective therapy. Do not self-discontinue from a viral post; bring the concern to the prescribing clinician and, if you have diabetes, keep up with retinal exams.

Pair the medicine with basics from day one: protein-forward small meals, fluids, and a plan for the first 30 days.

Injection vs pill: practical differences

Choosing a form is not only about “shots vs tablets.”

Weekly injection (Wegovy / Wegovy HD): One subcutaneous dose per week with a multi-week escalation built into the label. No empty-stomach ritual for the injection itself. Higher-strength Wegovy HD (7.2 mg) is an additional adult option after FDA approval under the National Priority Voucher program; your clinician decides whether any higher strength is appropriate.

Daily Wegovy pill: Oral semaglutide labeled for weight management needs careful timing—morning empty stomach, a small amount of plain water, then a waiting period before food, drink or other oral medicines. Miss the rules and absorption can suffer. People who travel, take many morning pills, or dislike injections may still prefer it; people who hate rigid morning routines may prefer the weekly pen.

Rybelsus is oral semaglutide for type 2 diabetes, not the Wegovy weight-management tablet. Same active ingredient family, different product and labeled use.

Muscle, protein and “quality” of weight loss

In STEP 1’s DXA substudy, fat mass and visceral fat fell, while absolute lean mass also declined even as the proportion of lean mass relative to total body weight improved. That pattern is common in weight-loss treatments. It is a reason clinicians and the 2025 joint nutrition advisory emphasize adequate protein and resistance training while appetite is low. Details live in how much protein you need on a GLP-1 and the high-protein eating guide.

Semaglutide is not a license to eat almost nothing. Very low intake raises dehydration, constipation, gallstone and muscle-loss risk.

How to read averages without fooling yourself

A 14.9% mean does not mean you will lose 14.9%. Trials enroll motivated volunteers, provide counseling, and still show wide individual ranges. NIDDK notes that even 5% to 10% loss can improve blood sugar, blood pressure and triglycerides—health gains that matter even when social media showcases larger transformations. Real-world analyses summarized in nutrition advisories often find somewhat smaller average losses than pivotal trials, which is expected when support and adherence differ.

What happens if you stop?

Obesity is a chronic disease. NIDDK says you will probably regain some weight after stopping a weight-management medication; keeping eating and activity habits may blunt how much returns. That is not a reason to avoid treatment—it is part of informed planning before you start.

Questions worth bringing to your clinician

1. Based on my BMI, conditions and history, am I a candidate for Wegovy or another FDA-approved option?
2. Injection, pill, or neither—and why for me?
3. How will we escalate the dose if I get nauseous?
4. How will we protect protein intake and muscle?
5. Do I have heart disease, sleep apnea or liver disease that changes the choice?
6. What will it cost with my insurance or cash programs?
7. What is the long-term plan if it works—or if it does not?

The bottom line

Semaglutide is a GLP-1 receptor agonist that helps many adults lose a clinically meaningful amount of weight by reducing appetite and food intake, with additional proven heart-risk benefit in people who already have cardiovascular disease. Large trials such as STEP 1 and SELECT, plus expanding 2025–2026 labels (oral Wegovy, Wegovy HD, MASH), make it one of the best-studied obesity medicines available—but it still causes frequent digestive side effects, carries rare serious risks, and works best with lifestyle support under medical supervision.

Explore more in our semaglutide hub, the GLP-1 Guide hub, and what is tirzepatide? if you are comparing options.